Bristol Raises Guidance on Demand for Eliquis, New Drugs
Bristol Myers Squibb Co. raised its 2024 earnings guidance after reporting better-than-expected revenue and profit, fueled by demand for the blood-thinner Eliquis and several newer treatments.Adjusted ...
Bristol Myers earnings beat expectations, driven by sales of older drugs
Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...
Dear Doctor: Here‘s why stopping prescription medications without a doctor’s OK can be dangerous
ANSWER: In general, I recommend against stopping prescription medications without your doctor telling you to, and I hope to ...
Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs
Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term ...
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious
Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...
BioSpace15d
BMS Delivers Q3 Beat, Raises 2024 Guidance Amid Strong Demand for Legacy and Newer Drugs
Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as ...
Bristol's New Schizophrenia Drug Cobenfy Helps Support Its Wide Moat
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
Seeking Alpha16d
Bristol-Myers raises outlook ahead of consensus after Q3 beat
The company reported $11.9B in revenue for the quarter with ~8% YoY growth as its blockbuster drugs Revlimid and Eliquis surpassed expectations, while sales from cancer therapy Opdivo slightly ...